Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

PTC: ‘Refuse to File’ Letter Leads to Job Cuts

By Mike Botta | March 24, 2016

South Plainfield, NJ – PTC Therapeutics, Inc. plans to cut its workforce by 18 percent in order to manage operating expenses following receipt from the FDA of a Refuse to File letter for its Translarna (ataluren) drug application.

In the letter received last month, the FDA stated that the application was not sufficiently complete to permit a substantive review. Despite the setback, company executives expressed the intention to “work with the FDA” in a subsequent attempt to bring Translarna to the U.S.

“While it is very difficult to part with this talented group of colleagues, it was a necessary step to better align our resources and enable us to continue our mission of bringing treatments to patients suffering from rare and neglected disorders,” Stuart W. Peltz, Ph.D., CEO said in a statement.

Completion of the cutback, which primarily will target its workers in the U.S., is expected by the end of June at an estimated $2.5 million in employee severance and benefit costs.

Meanwhile, efforts toward development and commercialization of Translarna outside of the U.S. will continue, according to the company.

Translarna (ataluren) is an oral protein restoration therapy for the treatment of nonsense mutation Duchenne muscular dystrophy. A nonsense mutation is an alteration in the genetic code that prematurely halts the synthesis of an essential protein.

The drug is conditionally approved in Europe for treatment in ambulatory patients who are five years of age and older. The European Medicines Agency had granted the conditional approval after a key committee decided that its “benefits are greater than its risks.”

Primarily affecting males, Duchenne muscular dystrophy is a progressive muscle disorder caused by the lack of functional dystrophin protein, critical to the structural stability of skeletal, diaphragm, and heart muscles.

Patients lose the ability to walk as early as age 10 and experience life-threatening lung and heart complications in their late teens and 20s, according to PTC, which estimated that nonsense mutations account for approximately 13 percent of DMD cases, or approximately 2,000 patients in the United States.

(Sources: PTC Therapeutics, Inc., European Medicines Agency)    

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news! 

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE